^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Melanoma
    Drug:pictilisib (GDC-0941) (PI3K inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Clin Cancer Res
    Title:

    First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors

    Excerpt:
    A patient with V600E BRAF-mutant melanoma and another with platinum-refractory epithelial ovarian cancer exhibiting PTEN loss and PIK3CA amplification demonstrated partial response by RECIST and GCIG-CA125 criteria, respectively.
    DOI:
    10.1158/1078-0432.CCR-14-0947